Twist Bioscience Corporation $TWST Stake Reduced by Amova Asset Management Americas Inc.

Key Points

• Amova Asset Management reduced its stake in Twist Bioscience by 7.8% in Q3 to 2,120,206 shares (about 3.51% ownership), worth roughly $59.6 million after selling 179,231 shares.
• Several large institutions increased holdings during the quarter — notably ARK Investment (now 6.73M shares, ~$189.3M) and Artisan Partners (added 1.35M shares) — signaling mixed but substantial institutional buying alongside Amova's reduction.
• Twist shows revenue growth (quarterly revenue up 16.9%) but a negative EPS and PE; analysts have a consensus rating of Moderate Buy with an average price target of ~$45.88 and several firms raising targets into the $50–$52 range.

Amova Asset Management Americas Inc. cut its stake in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 7.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,120,206 shares of the company's stock after selling 179,231 shares during the period. Amova Asset Management Americas Inc. owned 3.51% of Twist Bioscience worth $59,641,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. ARK Investment Management LLC increased its stake in shares of Twist Bioscience by 5.1% in the third quarter. ARK Investment Management LLC now owns 6,726,808 shares of the company's stock valued at $189,292,000 after purchasing an additional 326,367 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Twist Bioscience by 8.6% during the third quarter. Dimensional Fund Advisors LP now owns 790,893 shares of the company's stock worth $22,252,000 after buying an additional 62,300 shares during the period. William Blair Investment Management LLC grew its holdings in Twist Bioscience by 6.0% in the 3rd quarter. William Blair Investment Management LLC now owns 4,142,283 shares of the company's stock worth $116,564,000 after buying an additional 235,679 shares in the last quarter. Rafferty Asset Management LLC increased its position in Twist Bioscience by 51.0% in the 3rd quarter. Rafferty Asset Management LLC now owns 114,268 shares of the company's stock valued at $3,216,000 after acquiring an additional 38,608 shares during the period. Finally, Artisan Partners Limited Partnership raised its stake in Twist Bioscience by 26.7% during the 3rd quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company's stock valued at $180,403,000 after acquiring an additional 1,349,867 shares in the last quarter.

Twist Bioscience Price Performance

NASDAQ TWST opened at $48.06 on Thursday. The company has a current ratio of 3.78, a quick ratio of 3.37 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $57.88. The company has a market cap of $2.95 billion, a PE ratio of -37.55 and a beta of 2.23. The stock's 50-day moving average price is $43.03 and its two-hundred day moving average price is $34.31.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The firm had revenue of $103.70 million during the quarter, compared to analysts' expectations of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.Twist Bioscience's quarterly revenue was up 16.9% compared to the same quarter last year. On average, analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CAO Robert F. Werner sold 7,000 shares of the company's stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $45.65, for a total value of $319,550.00. Following the transaction, the chief accounting officer owned 58,738 shares in the company, valued at approximately $2,681,389.70. This represents a 10.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dennis Cho sold 5,000 shares of Twist Bioscience stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $49.93, for a total value of $249,650.00. Following the sale, the insider directly owned 138,581 shares of the company's stock, valued at approximately $6,919,349.33. The trade was a 3.48% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 36,609 shares of company stock valued at $1,665,151 in the last 90 days. Corporate insiders own 3.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on TWST shares. Barclays upped their price target on shares of Twist Bioscience from $39.00 to $50.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 3rd. Robert W. Baird set a $50.00 target price on Twist Bioscience in a research report on Tuesday, February 3rd. Evercore lifted their price target on Twist Bioscience from $42.00 to $52.00 and gave the company an "outperform" rating in a research report on Tuesday, February 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Twist Bioscience in a research note on Monday, December 29th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Seven investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, Twist Bioscience presently has a consensus rating of "Moderate Buy" and an average price target of $45.88.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.